seprafilm® Procedure Pack ADHESION BARRIER Re-order Number: 5086-02 Product Usage: Seprafilm Adhesion Barrier is indicated for use in patients undergoing abdominal or pelvic laparotomy as an adjunct intended to reduce the incidence, extent and severity of postoperative adhesions between the abdominal wall and the underlying viscera such as omentum, small bowel, bladder, and stomach, and between the uterus and surrounding structures such as tubes and ovaries, large bowel, and bladder.
Published June 27, 2012 · Recall initiated: June 13, 2012
Summary
FDA records medical device Class II recall Z-1855-2012, published June 27, 2012 and initiated June 13, 2012. Recalling firm: Genzyme Corporation; Status: Terminated; Reported quantity: 3880units; Lot: Lot numbers: 11NP620 Exp. 2014 - 09; 11NP630 Exp 2014 - 10; and 11NP649 Exp 2014- 11; 11NP704 Exp 2014 - 11. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Sterility of product may be compromised due to packaging defect
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Genzyme Corporation
- Distributor
- Worldwide Distribution - US (nationwide) and the country of S. Korea
- Lot
- Lot numbers: 11NP620 Exp. 2014 - 09; 11NP630 Exp 2014 - 10; and 11NP649 Exp 2014- 11; 11NP704 Exp 2014 - 11
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDAClolar (clofarabine) 20 mg/20 mL (1 mg/mL) Injection, for intravenous use, Rx Only, Mfd. by: Teva PharmachemieNovember 22, 2017
- FDAThyrogen (thyrotropin alfa for injection), 0.9 mg/mL after reconstitution, For intramuscular injection only,March 9, 2016
- FDAThyrogen (thyrotropin alfa for injection), 0.9 mg/mL after reconstitution, For intramuscular injection only,March 9, 2016
- FDAseprafilm® Single Site ADHESION BARRIER Re-order Number: 6641-01 Product Usage: Seprafilm Adhesion Barrier isJune 27, 2012
- FDAVerifyNow System, part #85005-6H Product Usage: The VerifyNow P2Y12 assay device is a whole blood assay usedJune 27, 2012
- FDAVerifyNow P2Y12 Assay, Part Number: 85064, All reagent lots. Product Usage: The VerifyNow P2Y12 assay deviceJune 27, 2012
Questions about this recall
Was seprafilm® Procedure Pack ADHESION BARRIER Re-order Number: 5086-02 Product Usage: Seprafilm Adhesion Barrier is indicated for use in patients undergoing abdominal or pelvic laparotomy as an adjunct intended to reduce the incidence, extent and severity of postoperative adhesions between the abdominal wall and the underlying viscera such as omentum, small bowel, bladder, and stomach, and between the uterus and surrounding structures such as tubes and ovaries, large bowel, and bladder. recalled?
Yes. FDA published recall Z-1855-2012 on June 27, 2012. Reported hazard: Sterility of product may be compromised due to packaging defect
What should I do if I have this product?
Voluntary: Firm initiated · Letter